Serum interferon gamma in primary biliary cirrhosis: Effect of ursodeoxycholic acid and prednisone therapy alone and in combination

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 4, 2000, Pages 463-468

  Fracchia, Mario ^a   Secreto, Paola ^a   Tabone, Marco ^a   Zaffino, Caterina ^a   Pera, Angelo ^a   Galatola, Giovanni ^a,b  

^a MAURIZIANO HOSPITAL   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

Corticosteroid; Interferon ; Prednisone; Primary biliary cirrhosis; Soluble inter cellular adhesion molecule 1; Ursodeoxycholic acid

Indexed keywords

GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PREDNISONE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL;

EID: 0033999740     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012040-00016     Document Type: Article

References (25)

1. 1 Galperin C, Coppel RL, Ansari AA, Gershwin ME. Immunopathology of vanishing bile duct syndrome, in: Vanishing Bile Duct Syndrome. Pathophysiology and Treatment. Alvaro D, Benedetti A, Strazzabosco M (editors). Dordrecht, Boston, London: Kluwer Academic Publishers; 1997. pp. 159-174.
2. 2 Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 1984; 11:1109-1113.
3. 3 Van den Oord JJ, Sciot R, Desmet VJ. Expression of MHC products by normal and abnormal bile duct epithelium. J Hepatol 1986; 3:310-317.
4. 4 Adams DH, Hubscher SG, Shaw J, Johnson GD, Babbs C, Rothlein R, et al. Increased expression of intercellular adhesion molecule-1 on bile ducts in primary cirrhosis and primary sclerosing cholangitis. Hepatology 1991; 14:426-431.
5. 5 Altman DM, Hogg N, Trowsdale J, Wilkinson D. Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen presenting cell function in mouse L cells. Nafure 1989; 338:512-514.
6. 6 Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand IDCAM-1 provides an important costimulatory signal for T-cell receptor mediated activation of resting T cells. J Immunol 1990; 144:4579-4589.
7. 7 Wawryk SO, Novotny JR, Wicks IP. The role of LFA-1/ICAM-1 interaction in human leucocyte homing and adhesion. Immunol Rev 1989; 108:135-161.
8. 8 Ayres RCS, Neuberger JM, Shaw J, Joplin R, Adams DH. Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of proinflammatory cytokines. Gut 1993; 34:1245-1249.
9. 9 Martinez OM, Villanueva JC, Gershwin ME, Krams SM. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology 1995; 21:113-119.
10. 10 Harada K, Van de Water J, Leung PSC, Coppel RL, Ansari A, Nakanuma Y, et al. In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of Th1 subset. Hepatology 1997; 25:791-796.
11. 11 Shindo M, Mullin GE, Braun-Elwert L, Bergasa NV, Jones EA, James SP. Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB). Clin Exp Immunol 1996; 105:254-259.
12. 12 Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM. Elevations in IFN-γ, IL-5 and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol 1996; 80:311-320.
13. 13 Rothlein R, Mainolfi EA, Czaikowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147:3788-3793.
14. 14 Lim AG, Jazrawi RP, Ahmed HA, Levy JH, Zuin M, Douds A, et al. Soluble Intercellular adhesion molecule-1 in primary biliary cirrhosis: relationship with disease stage, immune activity and cholestasis. Hepatology 1994; 20:882-888.
15. 15 Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113:884-890.
16. 16 Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992; 16:358-364.
17. 17 Lim AG, Wolfhagen FHJ, Verma A, van Buuren HR, Jazrawi RP, Levy J, et al. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic acid and immunosuppressive therapy. Eur J Gastroenterol Hepatol 1997; 9:155-161.
18. 18 Leuschner M, Güldütuna S, You T, Hübner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of primary biliary cirrhosis. J Hepatol 1996; 25:49-57.
19. 19 Ludwig J, Dickson ER, Mcdonald GSA. Staging of non-suppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch Pathol Anat Histopathol 1978; 379:103-112.
20. 20 Combes B, Carithers RL Jr, Maddry WC, et al. A randomised, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22:759-766.
21. 21 Tsuneyama K, van de Water J, Leung PSC, et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression. Hepatology 1995; 21:1031-1037.
22. 22 Beuers U, Kullak-Ublick GA, Paumgartner G. Mechanism of action of UDCA in cholestatic syndromes. In: Vanishing Bile Duct Syndrome. Pathophysiology and Treatment. Alvaro D, Benedetti A, Strazzabosco M (editors). Dordrecht, Boston, London: Kluwer Academic Publishers; 1997. pp. 230-239.
23. 23 Saeki R, Ogino H, Kaneko S, Unoura M, Kobayashi K. Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-gamma production by peripheral blood mononuctear cells from patients with primary biliary cirrhosis. J Gastroenterol 1995; 30:739-744.
24. 24 Fiocchi C, Fukushima K, Strong SA, Ina K. Pitfalls in cytokine analysis in inflammatory bowel disease. Aliment Pharmacol Ther 1996; 10(suppl 2):63-69.
25. 25 Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of Class I and Class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11:12-15.